We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $618B
1-Year Est. Return 30.34%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
+3.28%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+434.06%
AUM
$118B
AUM Growth
+$8.59B
Cap. Flow
-$401M
Cap. Flow %
-0.34%
Top 10 Hldgs %
16.92%
Holding
8,702
New
1,333
Increased
3,126
Reduced
2,721
Closed
1,293

Top Buys

Rank Stock Value
1
AMAT icon
Applied Materials
AMAT
+$346M
2
AVGO icon
Broadcom
AVGO
+$326M
3
BA icon
Boeing
BA
+$263M
4
COF icon
Capital One
COF
+$258M
5
OXY icon
Occidental Petroleum
OXY
+$257M

Sector Composition

Rank Sector Weight
1 Technology 7.15%
2 Financials 5.56%
3 Consumer Discretionary 5.28%
4 Industrials 4.73%
5 Healthcare 4.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RBBN icon
6651
PUT
Ribbon Communications
RBBN
$367M
$128K ﹤0.01%
+17,200
New +$127K
AVAL icon
6652
Grupo Aval
AVAL
$6.27B
$126K ﹤0.01%
15,201
+1,830
+14% +$15.1K
BCRX icon
6653
CALL
BioCryst Pharmaceuticals
BCRX
$2.51B
$126K ﹤0.01%
22,600
-25,700
-53% -$157K
CLDX icon
6654
CALL
Celldex Therapeutics
CLDX
$3.37B
$125K ﹤0.01%
3,380
+1,673
+98% +$74K
CPSS icon
6655
Consumer Portfolio Services
CPSS
$201M
$125K ﹤0.01%
27,502
+2,692
+11% +$12.2K
RST
6656
DELISTED
ROSETTA STONE INC
RST
$125K ﹤0.01%
+11,632
New +$130K
MACK
6657
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$125K ﹤0.01%
12,824
-23,131
-64% -$472K
VG
6658
PUT
DELISTED
Vonage Holdings Corporation
VG
$125K ﹤0.01%
19,100
+4,200
+28% +$28.1K
DXD icon
6659
PUT
ProShares UltraShort Dow 30
DXD
$42.3M
$124K ﹤0.01%
520
-35
-6% -$8.66K
BLCM
6660
CALL
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$124K ﹤0.01%
1,060
+30
+3% +$3.72K
AUD
6661
CALL
DELISTED
Audacy, Inc.
AUD
$124K ﹤0.01%
+12,000
New +$135K
PETX
6662
CALL
DELISTED
Aratana Therapeutics, Inc.
PETX
$124K ﹤0.01%
17,200
+4,600
+37% +$28.3K
RAS
6663
PUT
DELISTED
RAIT Financial Trust
RAS
$124K ﹤0.01%
56,400
+30,600
+119% +$78.7K
GSM icon
6664
FerroAtlántica
GSM
$865M
$122K ﹤0.01%
10,200
-210,675
-95% -$2.13M
GLUU
6665
PUT
DELISTED
Glu Mobile Inc.
GLUU
$122K ﹤0.01%
48,700
-14,300
-23% -$35.7K
LKM
6666
DELISTED
Link Motion Inc.
LKM
$122K ﹤0.01%
35,845
+14,818
+70% +$54.1K
UAN icon
6667
CVR Partners
UAN
$1.24B
$121K ﹤0.01%
3,453
+1,043
+43% +$45.5K
GER
6668
DELISTED
Goldman Sachs MLP Energy Renaissance Fund
GER
$121K ﹤0.01%
+1,866
New +$128K
LUMO
6669
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$120K ﹤0.01%
1,811
-1,222
-40% -$151K
HSTO
6670
PUT
DELISTED
Histogen Inc. Common Stock
HSTO
$120K ﹤0.01%
104
RSO
6671
CALL
DELISTED
Resource Capital Corp.
RSO
$120K ﹤0.01%
11,800
-5,900
-33% -$56.8K
BBDO icon
6672
Banco Bradesco
BBDO
$34.6B
$119K ﹤0.01%
+23,361
New +$132K
GGN
6673
GAMCO Global Gold, Natural Resources & Income Trust
GGN
$837M
$119K ﹤0.01%
+21,639
New +$123K
ANFI
6674
DELISTED
AMIRA NATURE FOODS LTD
ANFI
$119K ﹤0.01%
21,511
+7,087
+49% +$36K
EPE
6675
CALL
DELISTED
EP Energy Corporation
EPE
$119K ﹤0.01%
32,500
-58,300
-64% -$254K

Similar funds

Citadel Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Citadel Advisors held 8,702 positions worth $118B, up 7.8% from $109B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Citadel Advisors's Q2 2017 filing shows 1,333 new, 3,126 increased, 2,721 reduced and 1,293 closed positions. Its largest new stake was Equity Residential: 2,436,064 shares worth $160M. The largest sale was Walt Disney, an estimated $550M.

By sector, the portfolio is most concentrated in Technology at 7.1% of assets, up from 7.1% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Citadel Advisors's largest Q2 2017 buy was Equity Residential: 2,436,064 shares worth $160M.
  • Citadel Advisors added most to Applied Materials in Q2 2017, an estimated $346M increase.
  • Citadel Advisors's biggest Q2 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $549M.
  • Citadel Advisors fully exited Walt Disney in Q2 2017, selling an estimated $550M.
  • Citadel Advisors's ten largest holdings make up 17% of its $118B portfolio in Q2 2017.
  • Citadel Advisors opened 1,333 new positions and closed 1,293 in Q2 2017.
  • Citadel Advisors's portfolio value rose 7.8% quarter-over-quarter to $118B.

Based on Citadel Advisors's 13F filing for Q2 2017, filed 11 Aug 2017.